[go: up one dir, main page]

MX2012002385A - Inhibidores macrociclicos de cinasa janus. - Google Patents

Inhibidores macrociclicos de cinasa janus.

Info

Publication number
MX2012002385A
MX2012002385A MX2012002385A MX2012002385A MX2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A MX 2012002385 A MX2012002385 A MX 2012002385A
Authority
MX
Mexico
Prior art keywords
jak
macrocyclic inhibitors
macrocyclic
inhibitors
immune
Prior art date
Application number
MX2012002385A
Other languages
English (en)
Inventor
Alam Jahangir
Michael Soth
Stephen M Lynch
Hanbiao Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012002385A publication Critical patent/MX2012002385A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se relaciona con el uso de compuestos macrocíclicos nuevos de la fórmula (I), en donde las variables Q, Q1, Q2, Q3, y Q4 son definidas como se describió aquí, las cuales inhiben JAK y son útiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
MX2012002385A 2009-09-21 2010-09-17 Inhibidores macrociclicos de cinasa janus. MX2012002385A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24421609P 2009-09-21 2009-09-21
US37296910P 2010-08-12 2010-08-12
PCT/EP2010/063682 WO2011033053A1 (en) 2009-09-21 2010-09-17 Macrocyclic inhibitors of jak

Publications (1)

Publication Number Publication Date
MX2012002385A true MX2012002385A (es) 2012-04-02

Family

ID=43034482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002385A MX2012002385A (es) 2009-09-21 2010-09-17 Inhibidores macrociclicos de cinasa janus.

Country Status (11)

Country Link
US (1) US8318764B2 (es)
EP (1) EP2480554B1 (es)
JP (1) JP5540100B2 (es)
KR (1) KR101438293B1 (es)
CN (1) CN102498113B (es)
BR (1) BR112012006176A2 (es)
CA (1) CA2771176A1 (es)
ES (1) ES2509590T3 (es)
MX (1) MX2012002385A (es)
RU (1) RU2012116003A (es)
WO (1) WO2011033053A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2760453T3 (en) * 2011-09-30 2016-08-15 Ipsen Pharma Sas Macrocyclic LRRK2 kinase inhibitors
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
US9165142B1 (en) * 2013-01-30 2015-10-20 Palo Alto Networks, Inc. Malware family identification using profile signatures
WO2018153546A1 (en) * 2017-02-27 2018-08-30 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain
US11159538B2 (en) 2018-01-31 2021-10-26 Palo Alto Networks, Inc. Context for malware forensics and detection
US10764309B2 (en) 2018-01-31 2020-09-01 Palo Alto Networks, Inc. Context profiling for malware detection
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN113735856A (zh) * 2020-05-29 2021-12-03 百极弘烨(南通)医药科技有限公司 大环jak抑制剂及其应用
US11956212B2 (en) 2021-03-31 2024-04-09 Palo Alto Networks, Inc. IoT device application workload capture
US12212583B2 (en) 2021-09-30 2025-01-28 Palo Alto Networks, Inc. IoT security event correlation
WO2023208244A1 (zh) * 2022-04-29 2023-11-02 南京明德新药研发有限公司 大环类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
EP1066286B1 (en) 1998-03-04 2009-04-29 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
JP2007506787A (ja) * 2003-09-23 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとしてのピラゾロピロール誘導体
WO2008079521A2 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of janus kinase
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
WO2008060248A1 (en) * 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
KR101718384B1 (ko) 2008-06-10 2017-03-22 애브비 인코포레이티드 신규한 트리사이클릭 화합물

Also Published As

Publication number Publication date
BR112012006176A2 (pt) 2015-09-08
CN102498113B (zh) 2014-11-26
RU2012116003A (ru) 2013-10-27
WO2011033053A1 (en) 2011-03-24
KR101438293B1 (ko) 2014-09-05
CN102498113A (zh) 2012-06-13
EP2480554A1 (en) 2012-08-01
JP5540100B2 (ja) 2014-07-02
KR20120068940A (ko) 2012-06-27
US20110071179A1 (en) 2011-03-24
EP2480554B1 (en) 2014-08-06
ES2509590T3 (es) 2014-10-17
JP2013505219A (ja) 2013-02-14
US8318764B2 (en) 2012-11-27
CA2771176A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
MX2012002385A (es) Inhibidores macrociclicos de cinasa janus.
MX2010008198A (es) Inhibidores de cinasa de pirrolopirazina.
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
MX359032B (es) Inhibidores de pirrolopirazina cinasa.
MX2012002641A (es) Inhibidores de cinasa janus (jak).
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
ATE522534T1 (de) Pyrrolopyrazin-kinasehemmer
MX343561B (es) Compuestos de imidazolpiridazina.
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX342310B (es) Compuestos de tiazolopirimidina.
EA201170521A1 (ru) Новые соединения
MX352928B (es) Compuestos de piridazina-amida.
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
IN2012DN00869A (es)
PH12012501589A1 (en) Macrocycles as factor xia inhibitors
MY160468A (en) Novel amino azaheterocyclic carboxamides
GEP20135964B (en) Inhibitors of beta-secretase
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
MX2011011272A (es) Procesos e intermediarios.
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.

Legal Events

Date Code Title Description
FG Grant or registration